Mabwell (688062.SH, 02493.HK), an innovative pharmaceutical company with a fully integrated industrial chain, announced that its controlling subsidiary Myvision has entered into a strategic cooperation agreement with VivaVision, a leading ophthalmic small-molecule drug R&D company in China. The signing ceremony was successfully held in Shanghai on June 15.

You Weizhi, General Manager of Myvision, and Dr. Shen Wang, CEO of VivaVision, signed the strategic cooperation agreement, witnessed by core management teams from both sides.

Adhering to the principles of "complementary advantages, resource sharing, equality and mutual benefit, and long-term win-win cooperation," and focusing on unmet clinical needs in two core therapeutic areas, ocular inflammation and ocular immunology, the two parties will carry out comprehensive and in-depth collaboration. With Myvision's mature commercialization capabilities and VivaVision's exceptional clinical R&D strengths, they aim to bridge the entire chain from innovative drug development to market delivery, enhancing ophthalmic diagnosis and treatment standards in China, and creating greater value for clinicians and patients.

Dr. Liu Datao, Chairman and CEO of Mabwell, commented, "We are delighted to partner with VivaVision. Ophthalmology is an important part of Mabwell's age-related disease portfolio. VivaVision's strong focus on ophthalmology and robust new drug R&D capabilities make them an ideal partner. We look forward to mutually empowering each other and forging a new chapter of win-win cooperation."

Dr. Shen Wang, CEO of VivaVision, stated, "Myvision's core team has deep-rooted expertise and years of experience in the ophthalmic field, and their commercial operational capabilities are highly trustworthy. A quality pharmaceutical product requires not only proven efficacy but also professional commercial support. We look forward to deepening exchanges and expanding the boundaries of our collaboration in the future."

Going forward, Myvision and VivaVision will fully leverage their respective core strengths, continue to deepen their presence in ocular inflammation and immunology therapeutics, and accelerate the clinical translation and patient access of more high-quality ophthalmic drugs.

About Myvision

Myvision is a specialized commercialization platform focused on the full spectrum of ophthalmology, committed to becoming a trusted leader in China’s ophthalmic innovation ecosystem. Guided by its vision of “Driving Innovation, Uniting Vision and Empowering the Ophthalmic Ecosystem,” Myvision focuses on the fundamental treatment needs of ophthalmic diseases and is building an innovative product portfolio spanning near-, medium- and long-term horizons to maximize commercial value.

Myvision has built a portfolio of key ophthalmic products and product candidates, particularly in posterior-segment diseases, including adalimumab and aflibercept biosimilars, as well as established medicines covering ocular immunology, retinal and other posterior-segment diseases, dry eye and ocular surface disorders. Myvision actively seeks in-depth collaboration with external companies and physicians, focusing on two strategic priorities: first, clinical-engineering translational collaboration, through which Myvision works with clinical experts to accelerate the efficient translation of innovative technologies into ophthalmic products; and second, commercialization partnerships with external biopharmaceutical companies, through which Myvision provides end-to-end support for high-quality ophthalmic products from market access to academic promotion. Through an open and mutually beneficial partnership model, Myvision aims to integrate industry resources, accelerate patient access to innovative therapies, and continue to play a leading role in China’s ophthalmic innovation ecosystem.

About VivaVision

VivaVision is a clinical-stage biotechnology company dedicated to the development of innovative therapies for ophthalmic diseases. Founded by a world-class team of experts in ophthalmology and drug development, the company has built a differentiated ophthalmic drug discovery and development platform. Leveraging this platform, VivaVision has advanced multiple proprietary innovative drug candidates into clinical-stage development.